Thyroid Medicines — Medication Guide, Uses & Safety — Uses, Dosage & Side Effects | MyMedicPlus

Thyroid medicines treat conditions caused by an underactive (hypothyroidism) or overactive (hyperthyroidism) thyroid gland — two of the most common endocrine disorders globally, affecting an estimated 200 million people worldwide. The thyroid gland produces two key hormones — thyroxine (T4) and triiodothyronine (T3) — that regulate metabolism, body temperature, heart rate, energy, growth, and virtually every organ system. For hypothyroidism (insufficient thyroid hormone production), levothyroxine (synthetic T4) is the standard, highly effective, and well-tolerated replacement treatment. For hyperthyroidism (excessive thyroid hormone production, most commonly from Graves' disease or toxic nodular goiter), antithyroid thionamide drugs — carbimazole (UK/Europe), methimazole (USA/worldwide), and propylthiouracil (PTU, used especially in pregnancy first trimester and thyroid storm) — are used to suppress thyroid hormone synthesis. The most common cause of hypothyroidism is Hashimoto's autoimmune thyroiditis. The most common cause of hyperthyroidism is Graves' disease (autoimmune). All thyroid conditions require long-term management, regular blood test monitoring (thyroid-stimulating hormone/TSH, free T4, sometimes free T3), and individualized dose adjustment. Thyroid medicines are prescription-only drugs, managed by endocrinologists, thyroidologists, and general practitioners.

Levothyroxine is prescribed for a range of hypothyroid and thyroid conditions: primary hypothyroidism — including Hashimoto's autoimmune thyroiditis (the most common worldwide), post-thyroiditis (subacute and postpartum), iodine deficiency, and drug-induced hypothyroidism (from amiodarone, lithium, interferon, tyrosine kinase inhibitors); post-thyroidectomy hormone replacement (total or near-total thyroidectomy for cancer or Graves' disease); congenital hypothyroidism (cretinism — must be treated immediately after birth to prevent irreversible intellectual disability); TSH-suppression therapy in differentiated thyroid cancer (papillary, follicular) to reduce TSH stimulation of any residual malignant thyroid tissue — higher doses are used to suppress TSH below 0.1 mU/L in high-risk patients. Antithyroid drugs (carbimazole, methimazole, PTU) are used for: Graves' disease — given for 12–18 months as a 'block-and-replace' or titration regimen; toxic multinodular goiter — as a bridge before definitive treatment; toxic adenoma — pre-operative preparation; preparation for thyroid surgery (to normalize hormone levels and reduce gland vascularity); and as a bridge before radioactive iodine (RAI) ablation. PTU is specifically preferred in the first trimester of pregnancy (as carbimazole carries teratogenic risks — aplasia cutis and 'methimazole embryopathy'), and in thyroid storm (it additionally blocks peripheral T4-to-T3 conversion).

Levothyroxine is synthetic thyroxine (T4) — chemically identical to the T4 produced by the thyroid gland. After absorption from the small intestine, it binds to thyroid hormone transport proteins (primarily thyroxine-binding globulin, albumin) in the bloodstream and is distributed to tissues throughout the body. In peripheral tissues — particularly the liver, kidney, muscle, and brain — approximately 60–80% of T4 is converted to the biologically active triiodothyronine (T3) by deiodinase enzymes (specifically type 1 and type 2 iodothyronine deiodinases). T3 enters cells and binds to nuclear thyroid hormone receptors (TRα and TRβ), altering gene expression to regulate metabolic rate, thermogenesis, heart rate and contractility, gut motility, lipid metabolism, bone remodeling, and neurological function. Levothyroxine restores all these processes to normal by replacing the absent or insufficient natural T4. Antithyroid drugs (thionamides — carbimazole/methimazole, propylthiouracil) block thyroid hormone synthesis by inhibiting thyroid peroxidase (TPO) — the enzyme that oxidizes iodide to iodine and incorporates it into thyroglobulin to form T3 and T4. Without TPO activity, the thyroid gland cannot synthesize new hormone. The onset of action is gradual (2–4 weeks) because existing stored thyroid hormone must be depleted before blood levels fall. PTU additionally inhibits peripheral conversion of T4 to the more potent T3 by blocking type 1 deiodinase — which is why it is the drug of choice in thyroid storm where rapid reduction of active T3 is needed.

Levothyroxine dosing is precisely individualized and adjusted based on serum TSH (and free T4) blood test results, with the target TSH range typically 0.4–4.0 mU/L for most patients (lower for thyroid cancer TSH suppression). Starting dose: for healthy young adults without cardiac disease — 1.6 mcg/kg/day (e.g. 75–125 mcg for a 70 kg adult). For elderly patients, those with ischemic heart disease, or those with longstanding hypothyroidism — start at a much lower dose of 12.5–25 mcg once daily and titrate up very slowly by 12.5–25 mcg every 6–8 weeks to avoid precipitating angina or arrhythmias. For congenital hypothyroidism: 10–15 mcg/kg/day immediately after diagnosis. Maintenance doses typically range from 50 to 200 mcg daily. Administration is critically important: levothyroxine must be taken on an empty stomach with a full glass of water, 30–60 minutes before breakfast (or 4 hours before sleep if taken at night). Food, caffeine (coffee), calcium supplements, iron tablets, antacids, PPIs, and soy products all significantly reduce absorption if taken simultaneously. Carbimazole: 20–40 mg daily in divided doses initially (for titration regimen), reduced to a maintenance dose of 5–15 mg daily as thyroid hormone normalizes; for block-and-replace: 40 mg daily with concurrent levothyroxine 100 mcg daily. PTU: 200–600 mg daily in divided doses. All thyroid medicine doses are adjusted based on regular TSH testing every 6–8 weeks initially, then annually once stable. Never self-adjust thyroid medicine doses.

Levothyroxine, when taken at the correct individualized dose, causes no side effects — it simply replaces the hormone the body is failing to produce. All side effects of levothyroxine result from either too high a dose (over-replacement producing iatrogenic hyperthyroidism) or too low a dose (under-replacement producing continued or worsening hypothyroid symptoms). Excess levothyroxine produces hyperthyroid symptoms: palpitations and tachycardia, tremor, anxiety and irritability, insomnia, heat intolerance, sweating, diarrhea, weight loss, and menstrual irregularities. Chronically over-treated hypothyroidism (suppressed TSH below normal for prolonged periods) is associated with an increased risk of atrial fibrillation (approximately 3-fold increased risk) and osteoporosis/osteoporotic fractures, particularly in post-menopausal women. Starting levothyroxine too quickly (or at too high a dose) in elderly patients or those with ischemic heart disease can precipitate angina or myocardial infarction — always titrate slowly in these groups. Antithyroid drugs (carbimazole, PTU) common side effects: mild rash and urticaria (affecting 5–10%), joint pain (arthralgia), nausea, and altered taste sensation. Less commonly: a mild reduction in white blood cell count (leukopenia), which is usually asymptomatic and reversible. The most serious and potentially life-threatening side effect of antithyroid drugs is agranulocytosis — a severe and sudden drop in neutrophil (white blood cell) count that renders patients unable to fight bacterial infections. This is a medical emergency. Incidence: approximately 0.1–0.5% of carbimazole users, 0.3% of PTU users. It can occur at any time but most commonly within the first 3 months of treatment. Patients must be warned explicitly: any occurrence of fever, severe sore throat, mouth ulcers, or flu-like symptoms must trigger immediate emergency medical assessment and blood count measurement — do not wait to see if it improves. PTU can also cause drug-induced lupus and, rarely, severe liver damage (hepatotoxicity, including fulminant liver failure — more common with PTU than carbimazole, which is one reason PTU is generally avoided beyond the first trimester of pregnancy).

Levothyroxine has a very narrow therapeutic index — small changes in the dose taken or in its absorption can cause clinically significant changes in thyroid function. Absorption is critically affected by many common substances: take levothyroxine alone with water, and separate it by at least 4 hours from calcium supplements and calcium-rich foods, iron tablets, antacids, proton pump inhibitors (particularly omeprazole), cholestyramine, sucralfate, orlistat, and multivitamins containing calcium or iron. Coffee (even black) taken within 30–60 minutes significantly reduces absorption. Soy products and high-fiber foods reduce absorption. Different brands and formulations of levothyroxine are not always bioequivalent — try to remain on the same brand, and if a brand change is made, recheck TSH after 6–8 weeks. Pregnancy substantially increases levothyroxine dose requirements (typically by 25–50%) due to increased thyroxine-binding globulin and placental T4 metabolism — check TSH immediately on confirming pregnancy and every 4–6 weeks throughout. Antithyroid drugs (carbimazole, PTU): the single most important safety warning is to educate every patient about agranulocytosis. Every patient started on carbimazole or PTU must be given a written warning card and be explicitly told: if you develop fever, sore throat, or mouth ulcers, stop the antithyroid drug immediately and go to the nearest emergency department for an urgent blood count the same day — do not self-treat with antibiotics and do not wait. Never abruptly stop antithyroid drugs without medical guidance — this can precipitate rapid worsening of hyperthyroidism (thyroid storm in severe cases). Drug interactions for levothyroxine: amiodarone significantly impairs thyroid function (both hypo- and hyperthyroidism) and displaces T4 from binding proteins; warfarin — hyperthyroidism and excess levothyroxine increase warfarin sensitivity (lower warfarin dose may be needed as thyroid status improves); lithium and iodine-containing contrast media can worsen hypothyroidism; rifampicin reduces levothyroxine efficacy by increasing its metabolism.